Reply to letter by Schwartz et al

Affiliations

¹ Department of Medicine, Queen's University, Kingston, Ontario, Canada.
² Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
³ Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
⁴ Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.

Comment

Markus Kuksis et al. Neuro Oncol. 2021.

. 2021 Aug 2;23(8):1406-1407.

doi: 10.1093/neuonc/noab078.

¹ Department of Medicine, Queen's University, Kingston, Ontario, Canada.
² Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
³ Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
⁴ Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.

No abstract available

Comment in

Letter to the editor concerning Kuksis et al.
Schwartz NRM, Dalmat RR. Schwartz NRM, et al. Neuro Oncol. 2021 Aug 2;23(8):1404-1405. doi: 10.1093/neuonc/noab050. Neuro Oncol. 2021. PMID: 33982751 Free PMC article. No abstract available.

The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis.
Kuksis M, Gao Y, Tran W, Hoey C, Kiss A, Komorowski AS, Dhaliwal AJ, Sahgal A, Das S, Chan KK, Jerzak KJ. Kuksis M, et al. Neuro Oncol. 2021 Jun 1;23(6):894-904. doi: 10.1093/neuonc/noaa285. Neuro Oncol. 2021. PMID: 33367836 Free PMC article.

1. Komorowski AS, Warner E, MacKay HJ, Sahgal A, Pritchard KI, Jerzak KJ. Incidence of brain metastases in nonmetastatic and metastatic breast cancer: is there a role for screening? Clin Breast Cancer. 2020;20(1):e54–e64. - PubMed
1. Kuksis M, Gao Y, Tran W, et al. . The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis. Neuro Oncol. 2021;23(8):894–904. - PMC - PubMed
1. Canney P, Murray E, Dixon-Hughes J, Lewsley LA, Paul J. A prospective randomised phase III clinical trial testing the role of prophylactic cranial radiotherapy in patients treated with trastuzumab for metastatic breast cancer - Anglo Celtic VII. Clin Oncol (R Coll Radiol). 2015;27(8):460–464. - PubMed
1. Awada A, Colomer R, Inoue K, et al. . Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial. JAMA Oncol. 2016;2(12):1557–1564. - PubMed